Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KROS NASDAQ:RNA NASDAQ:WHWK NASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKROSKeros Therapeutics$10.15+1.0%$11.26$9.69▼$22.55$198.91M0.94272,016 shs178,205 shsRNAAvidity Biosciences$12.37-0.5%$13.11$11.40▼$16.77$211.60M0.93518,507 shs103,634 shsWHWKWhitehawk Therapeutics$4.16+2.5%$4.14$1.57▼$5.49$200.78M0.77265,195 shs161,368 shsXLOXilio Therapeutics$8.31+4.0%$8.23$6.47▼$12.74$52.53M-0.1225,310 shs12,327 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKROSKeros Therapeutics+1.21%-6.69%-13.73%-8.80%-27.12%RNAAvidity Biosciences+6.51%+1.06%-5.40%-9.60%-61.17%WHWKWhitehawk Therapeutics+1.00%-7.73%+3.57%+3.84%+405,999,900.00%XLOXilio Therapeutics+1.14%-3.85%+3.36%+11.62%-17.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKROSKeros Therapeutics$10.15+1.0%$11.26$9.69▼$22.55$198.91M0.94272,016 shs178,205 shsRNAAvidity Biosciences$12.37-0.5%$13.11$11.40▼$16.77$211.60M0.93518,507 shs103,634 shsWHWKWhitehawk Therapeutics$4.16+2.5%$4.14$1.57▼$5.49$200.78M0.77265,195 shs161,368 shsXLOXilio Therapeutics$8.31+4.0%$8.23$6.47▼$12.74$52.53M-0.1225,310 shs12,327 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKROSKeros Therapeutics+1.21%-6.69%-13.73%-8.80%-27.12%RNAAvidity Biosciences+6.51%+1.06%-5.40%-9.60%-61.17%WHWKWhitehawk Therapeutics+1.00%-7.73%+3.57%+3.84%+405,999,900.00%XLOXilio Therapeutics+1.14%-3.85%+3.36%+11.62%-17.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKROSKeros Therapeutics 2.25Hold$20.40100.99% UpsideRNAAvidity Biosciences 2.33Hold$70.29468.26% UpsideWHWKWhitehawk Therapeutics 2.50Moderate Buy$7.3376.28% UpsideXLOXilio Therapeutics 2.50Moderate Buy$28.00236.94% UpsideCurrent Analyst Ratings BreakdownLatest XLO, RNA, WHWK, and KROS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2026WHWKWhitehawk Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/26/2026XLOXilio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026RNAAvidity Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E-)5/15/2026KROSKeros Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/15/2026RNAAvidity Biosciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/8/2026XLOXilio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026WHWKWhitehawk Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.005/1/2026RNAAvidity Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral4/16/2026WHWKWhitehawk Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform4/16/2026WHWKWhitehawk Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$8.003/27/2026WHWKWhitehawk Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKROSKeros Therapeutics$244.06M0.82$4.63 per share2.19$15.51 per share0.65RNAAvidity Biosciences$36.68M5.77N/AN/A$10.88 per share1.14WHWKWhitehawk TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AXLOXilio Therapeutics$53.48M1.02N/AN/A$7.31 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKROSKeros Therapeutics$87.01M-$3.01N/AN/AN/A-256.60%-17.04%-15.84%8/5/2026 (Estimated)RNAAvidity Biosciences-$322.30MN/AN/AN/AN/A-3,650.39%-44.92%-39.57%N/AWHWKWhitehawk Therapeutics-$20.60M-$1.68N/AN/AN/AN/A-79.63%-74.01%N/AXLOXilio Therapeutics-$35.04M-$3.55N/AN/AN/A-58.52%-151.42%-27.61%8/13/2026 (Estimated)Latest XLO, RNA, WHWK, and KROS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026KROSKeros Therapeutics-$1.0229-$1.21-$0.1871-$1.21$1.93 million$0.37 million5/14/2026Q1 2026RNAAvidity Biosciences-$1.05-$0.97+$0.08-$0.97$2.00 million$19.64 million5/12/2026Q1 2026XLOXilio Therapeutics-$0.66-$0.58+$0.08-$0.58$8.52 million$12.65 million5/7/2026Q1 2026WHWKWhitehawk Therapeutics-$0.36-$0.32+$0.04-$0.32N/AN/A3/23/2026Q4 2025XLOXilio Therapeutics-$1.68-$0.85+$0.83$0.81$10.90 million$13.69 million3/12/2026Q4 2025WHWKWhitehawk Therapeutics-$0.55-$0.34+$0.21-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKROSKeros TherapeuticsN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/AWHWKWhitehawk TherapeuticsN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKROSKeros TherapeuticsN/A22.6122.62RNAAvidity BiosciencesN/A9.2011.57WHWKWhitehawk TherapeuticsN/A11.3611.36XLOXilio TherapeuticsN/A3.593.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKROSKeros Therapeutics71.56%RNAAvidity BiosciencesN/AWHWKWhitehawk Therapeutics52.08%XLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipKROSKeros Therapeutics20.60%RNAAvidity Biosciences3.83%WHWKWhitehawk Therapeutics49.90%XLOXilio Therapeutics7.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKROSKeros Therapeutics10019.79 million15.72 millionOptionableRNAAvidity Biosciences19017.11 million149.21 millionOptionableWHWKWhitehawk Therapeutics2149.45 million24.78 millionN/AXLOXilio Therapeutics706.58 million6.09 millionNot OptionableXLO, RNA, WHWK, and KROS HeadlinesRecent News About These CompaniesXilio Therapeutics (NASDAQ:XLO) Shares Down 0.3% - What's Next?June 9 at 2:14 AM | americanbankingnews.comXilio Therapeutics IncJune 2, 2026 | edition.cnn.comCancer Stocks That Are Advancing the Future of Oncology CareMay 18, 2026 | zacks.comXilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue EstimatesMay 12, 2026 | zacks.comXilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesMay 12, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2026 | globenewswire.comXilio Therapeutics (XLO) price target decreased by 28.57% to 20.40April 28, 2026 | msn.comXilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2April 17, 2026 | globenewswire.comXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of DirectorsApril 16, 2026 | markets.businessinsider.comXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.April 16, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2026 | globenewswire.comXilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?April 1, 2026 | zacks.comXilio Therapeutics (XLO) price target increased by 1,300.00% to 28.56March 28, 2026 | msn.comCancer Stocks to Buy as Innovation Reshapes Global Oncology MarketMarch 26, 2026 | zacks.comXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial ResultsMarch 23, 2026 | globenewswire.comXilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual MeetingMarch 17, 2026 | globenewswire.comXilio Therapeutics Announces 1-for-14 Reverse Stock SplitMarch 12, 2026 | globenewswire.comXilio Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceMarch 2, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 2, 2026 | globenewswire.comXilio Therapeutics Shareholders Approve Flexible Reverse Stock SplitFebruary 24, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX IPO: Opportunity? Or the Ultimate Hype Trade?By Chris Markoch | May 22, 2026Overextended, e.l.f. Beauty Is Primed to Rebound in Back HalfBy Thomas Hughes | May 22, 2026Japan's Stealth Bull Market: How U.S. Investors Can Get ExposureBy Chris Markoch | May 17, 2026Amazon vs. Alibaba: One Is Clearly The Better Value Play right NowBy Sam Quirke | May 14, 2026YETI Rallies After Earnings Beat and Raised OutlookBy Jennifer Ryan Woods | May 14, 2026XLO, RNA, WHWK, and KROS Company DescriptionsKeros Therapeutics NASDAQ:KROS$10.15 +0.10 (+1.00%) Closing price 04:00 PM EasternExtended Trading$10.15 +0.00 (+0.05%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Avidity Biosciences NASDAQ:RNA$12.37 -0.06 (-0.48%) As of 04:00 PM EasternAvidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Whitehawk Therapeutics NASDAQ:WHWK$4.16 +0.10 (+2.46%) Closing price 04:00 PM EasternExtended Trading$4.16 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.Xilio Therapeutics NASDAQ:XLO$8.31 +0.32 (+4.01%) Closing price 04:00 PM EasternExtended Trading$8.47 +0.16 (+1.97%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
